LETTER TO THE EDITOR Comment on alemtuzumab and inclusion body myositis
نویسنده
چکیده
Sir, The recent Brain publication (Dalakas et al., 2009) describing a clinical study of alemtuzumab in patients with inclusion body myositis nicely demonstrates the feasibility of enrolling and following a cohort of these patients over a long period of time as participants in an intervention study. The authors state that ‘in [inclusion body myositis] one series of alemtuzumab infusions can slow down disease progression up to 6 months’. Prior to publication of this paper in Brain, two scientific meeting abstracts and an editorial similarly reported results of this study as showing that, in inclusion body myositis, alemtuzumab may have a role in improving the clinical condition of patients (Dalakas et al., 2007a, b; Dalakas, 2008). Based on the Methods and Results now published in Brain, I have concerns that these conclusions may require further analysis for several reasons.
منابع مشابه
LETTER TO THE EDITOR Reply to: Comment on alemtuzumab and inclusion body myositis
Sir, Dr Greenberg misinterprets several important aspects of our study, including the scope and applied methodology. Below we have addressed the points raised in his correspondence. This was a proof-of principle molecular clinicopathological study designed to investigate the effect of alemtuzumab on endomysial T cells and disease progression; it was not primarily a trial of clinical efficacy. A...
متن کاملLETTER TO THE EDITOR Reply: Comment on alemtuzumab and inclusion body myositis
Sir, Dr Greenberg misinterprets several important aspects of our study, including the scope and applied methodology. Below we have addressed the points raised in his correspondence. This was a proof-of principle molecular clinicopathological study designed to investigate the effect of alemtuzumab on endomysial T cells and disease progression; it was not primarily a trial of clinical efficacy. A...
متن کاملComment on alemtuzumab and inclusion body myositis.
Sir, The recent Brain publication (Dalakas et al., 2009) describing a clinical study of alemtuzumab in patients with inclusion body myositis nicely demonstrates the feasibility of enrolling and following a cohort of these patients over a long period of time as participants in an intervention study. The authors state that ‘in [inclusion body myositis] one series of alemtuzumab infusions can slow...
متن کاملReply: Comment on alemtuzumab and inclusion body myositis
Sir, Dr Greenberg misinterprets several important aspects of our study, including the scope and applied methodology. Below we have addressed the points raised in his correspondence. This was a proof-of principle molecular clinicopathological study designed to investigate the effect of alemtuzumab on endomysial T cells and disease progression; it was not primarily a trial of clinical efficacy. A...
متن کامل